Positively Charged Polymers as Promising Devices against Multidrug Resistant Gram-Negative Bacteria: A Review
- PMID: 32456255
- PMCID: PMC7285334
- DOI: 10.3390/polym12051195
Positively Charged Polymers as Promising Devices against Multidrug Resistant Gram-Negative Bacteria: A Review
Abstract
Antibiotic resistance has increased markedly in Gram-negative bacteria, causing severe infections intractable with traditional drugs and amplifying mortality and healthcare costs. Consequently, to find novel antimicrobial compounds, active on multidrug resistant bacteria, is mandatory. In this regard, cationic antimicrobial peptides (CAMPs)-able to kill pathogens on contact-could represent an appealing solution. However, low selectivity, hemolytic toxicity and cost of manufacturing, hamper their massive clinical application. In the recent years-starting from CAMPs as template molecules-less toxic and lower-cost synthetic mimics of CAMPs, including cationic peptides, polymers and dendrimers, have been developed. Although the pending issue of hemolytic toxicity and biodegradability is still left not completely solved, cationic antimicrobial polymers (CAPs), compared to small drug molecules, thanks to their high molecular weight, own appreciable selectivity, reduced toxicity toward eukaryotic cells, more long-term activity, stability and non-volatility. With this background, an updated overview concerning the main manufactured types of CAPs, active on Gram-negative bacteria, is herein reported, including synthetic procedure and action's mechanism. Information about their structures, antibacterial activity, advantages and drawbacks, was reported in the form of tables, which allow faster consultation and quicker learning concerning current CAPs state of the art, in order not to retrace reviews already available.
Keywords: Gram-negative bacteria; antibiotic resistance; hemolytic cytotoxicity; membrane disruption; positively charged polymers.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





References
-
- Thaden J.T., Li Y., Run F., Maskarinec S.A., Hill-Rorie J.M., Wanda L.C., Reed S.D., Fowler V.G., Jr. Increased Costs Associated with Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Bacteria Are Due Primarily to Patients with Hospital-Acquired Infections. Antimicrob. Agents Chemother. 2017;61:e01709-01716. doi: 10.1128/AAC.01709-16. - DOI - PMC - PubMed
-
- WHO . Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline. WHO; Geneva, Switzerland: 2019.
-
- WHO . Antibacterial Agents in Preclinical Development: An Open Access Database. WHO; Geneva, Switzerland: 2019.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous